Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian Region
Launched by UNIVERSITY HOSPITAL OSTRAVA · May 29, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to improve the transport and use of a specialized mobile team that provides extracorporeal membrane oxygenation (ECMO) for patients who have experienced sudden cardiac arrest. ECMO is a treatment that can help support patients' hearts and lungs when they are not working properly. The goal is to see if having this mobile team available can help more patients receive this lifesaving treatment quickly and effectively.
To be eligible for the trial, participants must have had a cardiac arrest outside of a hospital and need a specific type of emergency treatment called ECPR. Unfortunately, those who have already passed away at the scene or cannot give consent cannot participate. If someone is eligible and decides to join, they can expect to be part of a study that aims to improve emergency care in their region. This trial is currently recruiting participants of all ages, so it’s an opportunity for many people to contribute to important advancements in cardiac care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • out-of-hospital cardiac arrest
- • indication for ECPR
- Exclusion Criteria:
- • death at the scene of the accident
- • withdrawal of the informed consent
About University Hospital Ostrava
University Hospital Ostrava is a leading medical research institution located in Ostrava, Czech Republic, dedicated to advancing healthcare through innovative clinical trials and research initiatives. As a prominent sponsor of clinical studies, the hospital combines cutting-edge medical technology with a commitment to patient-centered care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a focus on ethical standards and regulatory compliance, University Hospital Ostrava aims to contribute to the development of new therapies and improve treatment outcomes across various medical fields. Its robust research infrastructure and dedication to scientific excellence position it as a key player in the advancement of medical knowledge and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ostrava, Moravian Silesian Region, Czechia
Ostrava, Moravian Silesian Region, Czechia
Patients applied
Trial Officials
Nela Walachová, Mgr.
Principal Investigator
University Hospital Ostravs
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported